Scientists created a COVID-19 vaccine in under a year, but there remains no vaccine to stop the AIDS virus. Experts explain how HIV eludes defeat and describe their latest strategies.
The hunt for an AIDS vaccine approaches 40 with hope and caution
Latest News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: